WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive: Currently, TKIs, which are potent inhibitors of Bcr-Abl protein kinases, c-Kit and the platelet-derived growth factor receptor (Valk-Lingbeek et al., 2004; Slupianek et al., 2013), are widely used for treatment of CML due to their highly efficient control of CML at chronic phase.